BioCentury | Oct 5, 1998
Finance

Third Quarter Stocks: If not now, . . .

...do a combination like Axys," he said. Axys (AXPH, South San Francisco, Calif.) merged with Khepri...
BioCentury | Dec 8, 1997
Finance

Disgruntled

...be able to fully monetize Sequana's technology platform," as ARRS did with its acquisition of Khepri...
BioCentury | Jan 27, 1997
Company News

PE Applied Biosystems management update

...City, Calif. Business: Enabling technology Hired: Sandra McNamara, as VP of finance; formerly CFO of Khepri...
BioCentury | Nov 18, 1996
Company News

Arris, Merck deal

...acquired the targets to be used in the collaboration through its $22 million purchase of Khepri...
BioCentury | Nov 18, 1996
Analyst Picks & Changes

Analyst picks & changes

...the 1995 purchase of Khepri Pharmaceuticals, more than covers the $20 million purchase price for Khepri...
BioCentury | Nov 18, 1996
Finance

Return on invested capital

...with Merck. The transaction could more than cover the $22 million ARRS paid to acquire Khepri...
BioCentury | Jan 2, 1996
Company News

Arris, Khepri deal

...ARRS completed its acquisition of Khepri for 2.3 million ARRS common shares (see BioCentury Nov. 13...
...quarter for in-process R&D and acquisition costs. Arris Pharmaceutical Corp. (ARRS), South San Francisco, Calif. Khepri Pharmaceuticals Inc....
BioCentury | Aug 21, 1995
Company News

Khepri other research news

...the absence of specific, targeted proteases, Khepri said. The company is seeking collaborators for development. Khepri Pharmaceuticals Inc....
BioCentury | Jun 19, 1995
Company News

Khepri other research news

...in bone remodeling hasn't been well understood. The company is testing inhibitors in animal models. Khepri Pharmaceuticals Inc....
BioCentury | Apr 3, 1995
Company News

Khepri deal

...The South San Francisco company created Khepri Canada, a Montreal research hub focused on therapeutics based...
...focused on therapeutics based on proteases and protease inhibitors. Of the initial $7 million financing, Khepri...
...25 percent stake, respectively. Innovatech is a parapublic agency that operates as a venture fund. Khepri Pharmaceuticals Inc. WIR...
Items per page:
1 - 10 of 13
BioCentury | Oct 5, 1998
Finance

Third Quarter Stocks: If not now, . . .

...do a combination like Axys," he said. Axys (AXPH, South San Francisco, Calif.) merged with Khepri...
BioCentury | Dec 8, 1997
Finance

Disgruntled

...be able to fully monetize Sequana's technology platform," as ARRS did with its acquisition of Khepri...
BioCentury | Jan 27, 1997
Company News

PE Applied Biosystems management update

...City, Calif. Business: Enabling technology Hired: Sandra McNamara, as VP of finance; formerly CFO of Khepri...
BioCentury | Nov 18, 1996
Company News

Arris, Merck deal

...acquired the targets to be used in the collaboration through its $22 million purchase of Khepri...
BioCentury | Nov 18, 1996
Analyst Picks & Changes

Analyst picks & changes

...the 1995 purchase of Khepri Pharmaceuticals, more than covers the $20 million purchase price for Khepri...
BioCentury | Nov 18, 1996
Finance

Return on invested capital

...with Merck. The transaction could more than cover the $22 million ARRS paid to acquire Khepri...
BioCentury | Jan 2, 1996
Company News

Arris, Khepri deal

...ARRS completed its acquisition of Khepri for 2.3 million ARRS common shares (see BioCentury Nov. 13...
...quarter for in-process R&D and acquisition costs. Arris Pharmaceutical Corp. (ARRS), South San Francisco, Calif. Khepri Pharmaceuticals Inc....
BioCentury | Aug 21, 1995
Company News

Khepri other research news

...the absence of specific, targeted proteases, Khepri said. The company is seeking collaborators for development. Khepri Pharmaceuticals Inc....
BioCentury | Jun 19, 1995
Company News

Khepri other research news

...in bone remodeling hasn't been well understood. The company is testing inhibitors in animal models. Khepri Pharmaceuticals Inc....
BioCentury | Apr 3, 1995
Company News

Khepri deal

...The South San Francisco company created Khepri Canada, a Montreal research hub focused on therapeutics based...
...focused on therapeutics based on proteases and protease inhibitors. Of the initial $7 million financing, Khepri...
...25 percent stake, respectively. Innovatech is a parapublic agency that operates as a venture fund. Khepri Pharmaceuticals Inc. WIR...
Items per page:
1 - 10 of 13